Department of Biomedical, Metabolic and Neural Sciences, International Doctorate School in Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Via Campi 80, 41125, Modena, Italy.
Prenatal Medicine Unit, Obstetrics and Gynecology Unit, Department of Medical and Surgical Sciences for Mother, Child and Adult, University of Modena and Reggio Emilia, Via del Pozzo 71, 41125, Modena, Italy.
BMC Pregnancy Childbirth. 2023 Oct 13;23(1):726. doi: 10.1186/s12884-023-06044-z.
Despite being at higher risk of severe disease and pregnancy complications, evidence on susceptibility to SARS-CoV-2 infection in pregnancy is still limited. The aim of the study is to compare the likelihood of undergoing a SARS-CoV-2 test and testing positive for COVID-19 in pregnancy and puerperium with that of the general female population of reproductive age.
This is a retrospective population-based cohort study including 117,606 women of reproductive age (March 2020-September 2021) with 6608 (5.6%) women having ≥ 1 pregnancy. Women were linked to the pregnancy registry to be classified as "non-pregnant", "pregnant", and "puerperium"; then, according to the national case-based integrated COVID-19 surveillance system, all women undergoing a SARS-CoV-2 test during the study period were identified. The Incidence Rate Ratio was calculated to compare the likelihood of being tested for SARS-CoV-2 in pregnant, puerperium and non-pregnant women among all women included. The likelihood of having a COVID-19 diagnosis was calculated using two comparators (not-pregnant women and the person-time before/after pregnancy) by means of Cox proportional hazards models, adjusting for age and with the cluster option to control standard error calculation in repeated pregnancies. Only first infection and swabs before the first one positive were included.
The probability of being tested for SARS-CoV-2 was 4.9 (95% CI: 4.8-5.1) and 3.6 times higher (95%CI: 3.4-3.9) in pregnancy (including spontaneous miscarriages) and in the puerperium, respectively. The Hazard Ratio (HR) of covid-19 diagnosis during pregnancy vs. non-pregnancy was 1.17 (95% CI 1.03-1.33) with similar results when comparing the risk during pregnancy with that of the same women outside pregnancy (puerperium excluded), with an HR of 1.13 (95% CI 0.96-1.33); the excess decreased when excluding the test performed at admission for delivery (HR 1.08 (95%CI 0.90-1.30). In the puerperium, the HR was 0.62 (95% CI 0.41-0.92) comparing women with ≥ 1childbirth with all other women and excluding the first two weeks of puerperium.
Women during pregnancy showed a small increase in the risk of infection, compatible with a higher likelihood of being tested. A lower probability of infection during the puerperium was observed during the entire pandemic period, suggesting likely protective behaviors which were effective in reducing their probability of infection.
尽管妊娠女性患严重疾病和妊娠并发症的风险更高,但有关其对 SARS-CoV-2 感染易感性的证据仍然有限。本研究旨在比较妊娠和产褥期与育龄期普通女性相比进行 SARS-CoV-2 检测和 COVID-19 检测阳性的可能性。
这是一项回顾性基于人群的队列研究,纳入了 117606 名育龄期女性(2020 年 3 月至 2021 年 9 月),其中 6608 名(5.6%)女性有≥1 次妊娠。将女性与妊娠登记处相关联,分为“非妊娠”、“妊娠”和“产褥期”;然后,根据国家基于病例的综合 COVID-19 监测系统,确定在研究期间进行 SARS-CoV-2 检测的所有女性。计算发病率比值,以比较所有纳入女性中妊娠、产褥期和非妊娠女性进行 SARS-CoV-2 检测的可能性。使用 Cox 比例风险模型,使用两个对照(非妊娠女性和妊娠前/后时间)计算 COVID-19 诊断的可能性,调整年龄,并使用聚类选项控制重复妊娠时标准误差的计算。仅纳入首次感染和首次阳性前的拭子。
进行 SARS-CoV-2 检测的概率分别为 4.9(95%CI:4.8-5.1)和 3.6 倍(95%CI:3.4-3.9)在妊娠(包括自然流产)和产褥期。与非妊娠相比,妊娠期间 COVID-19 诊断的危害比(HR)为 1.17(95%CI 1.03-1.33),当将妊娠期间的风险与妊娠以外的同一女性(产褥期除外)的风险进行比较时,结果相似,HR 为 1.13(95%CI 0.96-1.33);当排除分娩时的检测时,风险会降低(HR 1.08(95%CI 0.90-1.30)。在产褥期,与所有其他女性相比,与≥1 次分娩的女性相比,HR 为 0.62(95%CI 0.41-0.92),并排除了产褥期的前两周。
妊娠女性感染风险略有增加,这与更有可能进行检测相符。整个大流行期间,产褥期感染的可能性较低,这表明可能采取了有效的保护行为,降低了她们感染的可能性。